| Jul 29 |
NeoGenomics: Q2 Earnings Snapshot
|
| Jul 29 |
NeoGenomics Non-GAAP EPS of $0.03 beats by $0.03, revenue of $165M beats by $3M
|
| Jul 29 |
NeoGenomics Reports Second Quarter 2024 Results
|
| Jul 28 |
NeoGenomics Q2 2024 Earnings Preview
|
| Jul 22 |
NeoGenomics (NASDAQ:NEO) shareholders have endured a 68% loss from investing in the stock three years ago
|
| Jul 20 |
Is NeoGenomics, Inc. (NEO) the Most Profitable Stock of the Last 20 Years?
|
| Jul 12 |
Injunction against NeoGenomics over RaDaR assay affirmed by appeals court
|
| Jul 9 |
NeoGenomics to Report Second Quarter 2024 Financial Results on July 29, 2024
|
| Jun 13 |
Fort Myers’ Mayor to Proclaim June as NeoGenomics’ Commitment to Cancer Month
|
| May 28 |
NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management
|
